Company news
NovoCure Limited news in 2021
NovoCure Limited's news releases, calls and decks from 2021, newest first.
Novocure Signs Agreement to Acquire and Construct Building in Downtown Portsmouth, New Hampshire
December 6, 2021
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
December 5, 2021
Novocure to Participate in Two Upcoming Investor Conferences
November 22, 2021
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
November 21, 2021
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
November 14, 2021
2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma
November 14, 2021
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
October 27, 2021
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
October 27, 2021
Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting
October 20, 2021
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
October 3, 2021
Novocure to Report Third Quarter 2021 Financial Results
October 3, 2021
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
October 3, 2021
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
September 13, 2021
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
September 8, 2021
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
September 1, 2021
Novocure Appoints Bill Burke as Chief Human Resources Officer
August 31, 2021
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
July 28, 2021
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
July 14, 2021
Novocure to Report Second Quarter 2021 Financial Results
July 7, 2021
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
June 30, 2021
Novocure Initiates Usability Study for Flexible Torso Array
June 15, 2021
Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma
May 24, 2021
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
May 17, 2021
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
April 28, 2021
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
April 21, 2021
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
April 12, 2021
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
April 12, 2021
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
April 8, 2021
Novocure to Report First Quarter 2021 Financial Results
March 31, 2021
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
February 24, 2021
Novocure Announces Addition to Its Board of Directors
February 7, 2021
Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update
January 10, 2021